Abilify as a monotherapy

ABILIFY (aripiprazole) is indicated for the acute and maintenance treatment of manic episodes associated with Bipolar I Disorder as monotherapy in adults Aripiprazole was initially approved to treat schizophrenia and later approved for bipolar mania, as a monotherapy and an adjunctive therapy (manic or mixed

19 Sep 2013 Two trials found that Abilify was no better than placebo as monotherapy for bipolar depression. Abilify39s most bothersome side effect in these

Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100- week, double-blind study versus placebo. Keck PE Jr(1), Calabrese JR, McIntyre Abilify Maintena: 400 mg IM once monthly continue treatment with Monotherapy: 15 mgday PO initially may be increased gradually not to exceed 30 mgday ABILIFY is indicated for the acute treatment of manic and mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or

ABILIFY (aripiprazole) Bipolar I Disorder (Manic or Mixed

12 May 2010 Abilify is FDA approved for the treatment of bipolar disorder and is Monotherapy is the use of one medication to treat a particular disorder These highlights do not include all the information needed to use ABILIFY .. of ABILIFY is 15 mgday, as monotherapy or as adjunctive therapy with lithium or

17 Feb 2011 Abilify is also approved as monotherapy for the acute treatment of manic or mixed episodes associated with Bipolar I Disorder and for the To evaluate the efficacy and safety of aripiprazole as acute and maintenance of effect monotherapy for acute bipolar mania.Patients with acute bipolar I mania (